REGULATORY

MHLW Official Reveals Rationales Behind Off-Year Decision, Says PMP Return Is Reasonable

By Ken Yoshino January 8, 2025

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The decision late last year to implement deferred price cuts for the price maintenance premium (PMP) in the FY2025 off-year drug price revision is reasonable even though it might be a big blow to some companies, a senior health ministry…

To read the full story

Gist of FY2025 Drug Price Revision
December 26, 2024
Chuikyo OKs Outline of FY2025 Off-Year Drug Price Revision
December 26, 2024

REGULATORY

PMDA Urges Proper Use of Colchicine, Advises against High-Dose Administration
February 12, 2026
PMDA to Offer Priority Consultations for Overseas Startups
February 12, 2026
Japan OKs 2nd OTC Emergency Contraceptive, Launch Set for March 9
February 12, 2026
LDP Wins Landslide Victory in Lower House Election; Ex-Lawmakers Return as Centrists Routed
February 9, 2026
MHLW Panel Deems 10 “Drug Loss” Products as High-Need, to Seek Development
February 9, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision

By Ken Yoshino

Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…